Exhibit 10.52

 

FIRST AMENDMENT TO AMENDED AND RESTATED

SALES REPRESENTATIVE AGREEMENT

 

THIS FIRST AMENDMENT TO AMENDED AND RESTATED SALES REPRESENTATIVE AGREEMENT (the
“Amendment”) is made as of March 6, 2005 (the “Effective Date”), by and between
Micro Therapeutics, Inc., a Delaware corporation (“MTI”) and ev3 International,
Inc., a Delaware corporation (“ev3”) and amends that certain Amended and
Restated Sales Representative Agreement, dated as of August 4, 2003, by and
between MTI and ev3 (the “Agreement”). Capitalized terms not defined herein
shall have the meanings ascribed to them in the Agreement.

 

RECITALS

 

WHEREAS, MTI and ev3 entered into the Agreement to set forth the terms and
conditions upon which ev3 would provide sales services to MTI for sales of the
Products;

 

WHEREAS, MTI and ev3 desire to amend the Agreement as set forth in this
Amendment; and

 

WHEREAS, Section 19 of the Agreement provides that no amendment to the Agreement
may be enforced unless in writing and signed by each of MTI and ev3.

 

AGREEMENT

 

NOW, THEREFORE, the parties agree to amend the Agreement as follows:

 

1. Section 13(a) of the Agreement is hereby amended and restated in its entirety
to read as follows:

 

“Term. This Agreement will become effective on the Effective Date and continue
in effect until November 16, 2006, unless earlier terminated pursuant to Section
13(b). This Agreement will automatically renew for subsequent 1 year periods
unless either party provides the other party written notice 180 days prior to
the expiration of the initial term or any renewal term of its intention not to
renew.”

 

2. Section 13(b)(iii) of the Agreement is hereby amended and restated in its
entirety to read as follows:

 

“the direct or indirect ownership or control of the other party changes as
follows: MTI may only exercise its right of termination under this Section in
the event that Warburg Pincus (together with its affiliates) ceases to own or
control at least 40% of ev3, or its ultimate parent entity. ev3 may only
exercise it’s right of termination under this Section if a third party gains
control of MTI from, or subsequent to, Warburg Pincus (together with its
affiliates). Control of MTI will be deemed to have changed to a third party if
that party acquires control over more shares of MTI than Warburg Pincus
(together with its affiliates) controls at that point in time. For purposes of
this Section, an initial public offering of a party will not be considered to
create a right of termination under this Agreement.”

 

3. Except as amended hereby, the terms and conditions of the Agreement shall
remain in full force and effect.

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly
executed as of the date first written above.

 

Micro Therapeutics, Inc.    ev3 International, Inc. By:   

/s/ Thomas C. Wilder, III

--------------------------------------------------------------------------------

   By:   

/s/ James Corbett

--------------------------------------------------------------------------------

    

Thomas C. Wilder, III, President and

Chief Executive Officer

        James Corbett, President and Chief Executive Officer

 

2